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Neonatal alloimmune
thrombocytopenia due to HPA-3a
antibodies: a case report
A. DAVOREN, G. SMITH, G. LUCAS, S. RODGERS, P. O’DONOGHUE, J. CROWLEY, C.A. BARNES,  AND J. MCKIERNAN
A healthy infant was born at term by elective cesarean section to a
32-year-old para 4, gravida 4, mother.  Within 24 hours, the infant
was noted to have fairly extensive bruising on the back and
shoulders.  A full blood count evaluation was remarkable for severe
thrombocytopenia (platelet count of 29 × 109/L). Other hema-
tologic parameters were normal. Human leukocyte antigen (HLA)
class-1 antibodies but not platelet-specific antibodies were
detectable in the maternal serum using a commerical antigen-
capture ELISA (GTI-PakPlus kit®).  Anti-HPA-3a antibodies, while
weakly reactive in the monoclonal antibody immobilization of
platelet antigens (MAIPA) assay in the immediate postpartum
serum, were readily detectable using this assay in a sample taken 4
weeks later. Genotyping for human platelet antigens (HPA) 1–5 by
the polymerase chain reaction technique with sequence-specific
primers (PCR-SSP) revealed the infant’s platelet genotype to be
HPA-1a/1a, 3a/3b, while that of the mother was HPA-1a/1a, 3b/
3b, consistent with a diagnosis of anti-HPA-3a neonatal alloimmune
thrombocytopenia (NAIT).  This case illustrates the increased
sensitivity of the MAIPA technique for the detection of platelet-
specific antibodies.  We believe this to be the first serologically
confirmed case of NAIT due to anti-HPA-3a to be reported in the
republic of Ireland. Immunohematology 2002;18:33–36.
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Neonatal alloimmune thrombocytopenia (NAIT) is
the result of platelet destruction by maternal IgG
alloantibodies directed against antigens on fetal/
neonatal platelets.1 It occurs in approximately 1 in 1000
live births.2,3 Clinical sequelae vary from asymptomatic
thrombocytopenia in some infants to intracranial
hemorrhage in the more severely affected cases.3,4
There is a reported mortality in NAIT of up to 10
percent of affected infants, while a further 10–20
percent suffer varying degrees of neurologic
impairment due to intracranial hemorrhage.5–7
Several human platelet antigen (HPA) systems have
been identified.8 Most are biallelic, with the high-
frequency antigen being designated the “a” antigen and
the low-frequency antigen, the “b” antigen. HPA-1a is the
most clinically relevant platelet antigen in Caucasians,
with anti-HPA-1a alloimmunization in HPA-1b homo-
zygous mothers accounting for approximately 85
percent of cases of NAIT.4 An additional 10–15 percent
of cases are caused by HPA-5b antibodies.4 NAIT due to
other platelet antigen incompatibilities is relatively
uncommon.  We describe a case of NAIT due to
maternal HPA-3a alloimmunization.
Case Report
A 32-year-old mother gave birth to her fourth child
by elective cesarean section after an uncomplicated
pregnancy. She had three previous healthy children and
an uncomplicated obstetric and perinatal history. She
had not taken any medications during her current
pregnancy, had no history of blood transfusion, was
immune to rubella, and was negative for hepatitis B
surface antigen.
The male infant (birth weight: 3820 g) was generally
healthy at birth, with Apgar scores of 9 and 10 at 1 and
5 minutes, respectively.  Approximately 24 hours after
delivery, the infant was noted to be irritable and
physical examination revealed the presence of
petechiae and bruising on the left arm and back,
extending to the right shoulder region.  The infant’s
platelet count was 29 × 109/L, hemoglobin 16.4 g/dL,
activated partial thromboplastin time (APTT) 34
seconds (control 26 to 32 seconds), and international
normalized ratio (INR) 1.3. Red and white blood cell
counts were normal.  There was no evidence of
infection, malformation, hemangioma or hepatosple-
nomegaly.  The maternal platelet count was normal and
there was no familial history of bleeding disorders or
NAIT. Blood cultures were negative.  A clinical diagnosis
of NAIT was made and the infant was observed closely
in the special care baby unit, where he remained well
with no extension of bruising, and his behavior was
normal. Platelet transfusion was not required.  At
discharge on day 7, the infant’s platelet count was 118
× 109/L.  At follow-up 4 weeks after discharge from the
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hospital, the baby was developing normally and had a
normal platelet count (353 × 109/L).
Materials and Methods
A maternal serum sample, obtained after delivery, was
tested for platelet-reactive antibodies, using a
commercial antigen-capture enzyme-linked immu-
nosorbent assay (ELISA) kit (GTI-PakPlus® ELISA, Quest
Biomedical, Knowle,  West Midlands, UK).9 This kit was
used with an IgG conjugate and in accordance with the
manufacturer’s instructions.  The mother’s serum was
also referred to the International Blood Group
Reference Laboratory (IBGRL), Bristol, UK, for testing by
the platelet suspension immunofluorescence technique
(PSIFT)10 and by the monoclonal antibody immo-
bilization of platelet antigens (MAIPA) assay.11 The
immunofluorescence test was assessed by the use of
flow cytometry.  A maternal serum sample obtained 4
weeks later for repeat investigation was referred to both
the IBGRL and the Platelet Immunology Reference
Laboratory, National Blood Service, Cambridge, UK. HPA
genotyping was performed using the polymerase chain
reaction technique with sequence-specific primers
(PCR-SSP) for HPA 1–5.12
Results
Human leukocyte antigen (HLA) antibodies class-I,
but not platelet-specific antibodies, were detectable in
both the serum sample obtained after delivery and the
repeat sample taken 4 weeks later, using the GTI
PakPlus® kit.  The patient’s serum bound both IgG and
IgM to the surface of platelets in the immuno-
fluorescence test.  While weakly reactive HPA-3a
antibodies were identified by the MAIPA assay in the
immediate postpartum serum, in addition to HLA class-
I antibodies, anti-HPA-3a was readily detectable in a
sample taken 4 weeks later.
The mother’s platelet genotype was HPA-1a/1a, HPA-
3b/3b, and the infant typed as HPA-1a/1a, HPA-3a/3b,
as determined by PCR-SSP.  These results were
consistent with a diagnosis of NAIT due to maternal
HPA-3a antibodies. Paternal platelets were unavailable
for typing or crossmatch studies with maternal serum.
Discussion
NAIT occurs in approximately 1 in 1000 preg-
nancies.2,3 HPA-1a antibodies account for about 85
percent of cases and anti-HPA-5b for 10–15 percent of
cases.4 NAIT resulting from alloimmunization to the
HPA-3a (Baka) antigen in HPA-3b homozygous mothers
is rare (< 1% of documented cases).4
Of 27 cases of serologically confirmed NAIT
diagnosed in Ireland between January 1992 and
December 2000 (A. Davoren, in press), 25 (93%) were
due to HPA-1a antibodies, one was due to HPA-5b
antibodies, and one (this case) was due to HPA-3a
antibodies. In the study by Mueller-Eckhardt, et al.,4 only
one out of 121 serologically confirmed cases of NAIT
was due to HPA-3a antibodies.
Antibodies to the HPA-3a (Baka) antigen system were
originally described in 198013 and the antigen was
localized to glycoprotein IIa. In that first reported case,
the first child of a healthy mother developed severe
thrombocytopenia and died of a cerebral hemorrhage
on day 4 of life. Only a small number of cases have been
reported since 1980 but all have been associated with
severe thrombocytopenia (platelet count < 30 × 109/
L).14–20 One infant sustained an intracranial hemorrhage
with residual hemiparesis, mental retardation, and
epilepsy.19 Thus, although HPA-3a would appear to be
significantly less immunogenic than either HPA-1a or
-5b, NAIT caused by HPA-3a antibodies is similar in its
severity to anti-HPA-1a–induced disease.20 Furthermore,
the duration of thrombocytopenia associated with HPA-
3a alloimmunization may be prolonged.19
Improvements in platelet antibody detection
techniques and PCR technology have led to increased
diagnosis of NAIT in recent years. However,
considerable inconsistency in test results between
laboratories continues to be reported for antibodies
other than anti-HPA-1a.21 The fragility of the Baka
epitopes has been demonstrated previously and may
account for the difficulties sometimes encountered in
the detection of these antibodies.22,23
The use of a commercial antigen-capture ELISA (GTI
PakPlus®) failed to detect the HPA-3a antibody in this
case. In contrast, the MAIPA assay was able to detect
HPA-3a antibodies in both the immediate postpartum
serum sample (weakly) and, more readily, in the sample
taken 4 weeks later.
The advantages of the MAIPA assay for HPA
alloantibody detection compared to the GTI kit have
been previously documented.9 In the MAIPA technique,
monoclonal antibodies are used to isolate the various
platelet glycoproteins from each other, thus permitting
analysis of mixtures of antibodies directed against
different antigens.11
This case highlights potential difficulties that may be
encountered in the detection of platelet-specific
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antibodies and illustrates that more than one assay,
combined with platelet genotyping, may be required for
the diagnosis of NAIT.  Weak or undetectable antibodies
can be boosted to readily detectable levels in the weeks
after delivery.  Thus, it is important to obtain follow-up
samples from patients where there is a strong clinical
suspicion of NAIT.  Accurate characterization of the
responsible platelet-specific antibody is important to
enable appropriate counseling of the parents regarding
future pregnancies and to avoid complications if blood
transfusions are required.
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